June 10, 2021 Ultrasound is a useful guide in determining lung congestion for hemodialysis patients at high cardiovascular risk, according to research presented on June 6 at the European Renal Association European Dialysis and Transplant Association virtual congress.
A team of researchers led by Dr. Claudia Torino from the National Research Council of Italy found that patients with end-stage kidney disease who underwent lung ultrasound showed significantly less frequent episodes of decompensated heart failure and major cardiovascular events. Ultrasound examinations are available virtually everywhere in the hospital environment and do not take long to perform, so they can be deployed to diagnose and treat an ominous complication like lung congestion in hemodialysis patients, Torino said.
Complement Inhibitor Shows Early Promise in IgA Nephropathy
medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
Targeted News Service
targetednews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from targetednews.com Daily Mail and Mail on Sunday newspapers.
Ardelyx Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Highlights
Company well positioned for PDUFA date of April 29, 2021 and the potential launch of tenapanor
News provided by
Share this article
Share this article
FREMONT, Calif. and WALTHAM, Mass., March 8, 2021 /PRNewswire/ Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiorenal diseases, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2020. The stage is set for an exciting year for Ardelyx in 2021 said Mike Raab, president and chief executive officer at Ardelyx. With our PDUFA date of April 29 rapidly approaching, we are well positioned and well prepared to commercialize tenapanor upon potential FDA approval of the first and only phosphate absorption inhibitor for the control of serum phosphorus. In addition,